CSI Market
Sign In | Register

Aligos Therapeutics Inc (ALGS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ALGS quarterly Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Aligos Therapeutics Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-24.19
Depreciation & amortization0.93
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-0.15
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation5.04
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-60.18
Operating Lease Right Of Use Asset Amortization Expense1.88
Derivative Gain Loss On Derivative Net-
Minority Interest Change In Redemption Value-
Increase Decrease In Right Of Use Assets-
Increase Decrease In Operating Lease Liabilities-3.11
Leasehold Improvement Directly Paid By The Landlord-
Right Of Use Asset Obtained In Exchange For Finance Lease Liability-
Market To Market Adjustment For Available For Sale Investments-
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable1.41
Increase (Decrease) in Accrued Liabilities-2.03
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.10
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.19
Discontinued operations0.00
Net Cash flow from Operating Activities-82.50
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale, Maturity and Collection of Short-term Investments-37.39
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Purchases Write Offs Of Property And Equipment-0.44
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-37.83
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.30
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net64.24
Payments On Deferred Offering Costs-
Finance Lease Principal Payments-0.01
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents37.11
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities101.64
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-82.50
Total Cash Flow-18.69
4 historic quarters locked

Sign in to unlock the full Aligos Therapeutics Inc cash flow history.

Sign In Create Free Account

About Aligos Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-092614

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License